ProShare Advisors
XFOR icon

ProShare Advisors’s X4 Pharmaceuticals XFOR Stock Holding History

ProShare Advisors’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,231
Closed -$8.73K – 2197
2025
Q1 		$8.73K Sell
1,231
-347
-22% -$4.78K ﹤0.01% 2071
2024
Q4 		$34.7K Sell
1,578
-539
-25% -$8.59K ﹤0.01% 2226
2024
Q3 		$42.5K Buy
2,117
+1,558
+279% +$32.5K ﹤0.01% 1993
2024
Q2 		$9.73K Sell
559
-191
-25% -$6.25K ﹤0.01% 1836
2024
Q1 		$31.3K Buy
750
+71
+10% +$1.98K ﹤0.01% 1953
2023
Q4 		$17.1K Buy
679
+146
+27% +$3.55K ﹤0.01% 1924
2023
Q3 		$17.4K Sell
533
-1
-0.2% -$44 ﹤0.01% 1794
2023
Q2 		$31.1K Buy
+534
New +$27.4K ﹤0.01% 1812

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

ProShare Advisors's XFOR Position: Q2 2025 in Review

ProShare Advisors sold out of X4 Pharmaceuticals (XFOR) in Q2 2025, closing a stake of 1,231 shares — an estimated $8.73K sold.

ProShare Advisors first reported a position in XFOR in Q2 2023 and held it in 8 quarters. The position peaked at $42.5K in Q3 2024. 51 funds tracked by Wall St. Rank hold XFOR as of Q2 2025.

  • ProShare Advisors reported no remaining X4 Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • ProShare Advisors sold 1,231 X4 Pharmaceuticals shares in Q2 2025, an estimated $8.73K.
  • ProShare Advisors first reported a position in X4 Pharmaceuticals in Q2 2023 and held it in 8 quarters.
  • ProShare Advisors's X4 Pharmaceuticals position peaked at $42.5K in Q3 2024.
  • 51 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2025.

Based on ProShare Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.